Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Regen BioPharma (RGBP) over the last 4 years, with Q2 2025 value amounting to -$0.01.

  • Regen BioPharma's EPS (Weighted Average and Diluted) rose 6666.67% to -$0.01 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.2, marking a year-over-year change of 0.0%. This contributed to the annual value of -$0.16 for FY2024, which is 15618.39% down from last year.
  • Latest data reveals that Regen BioPharma reported EPS (Weighted Average and Diluted) of -$0.01 as of Q2 2025, which was up 6666.67% from -$0.0 recorded in Q1 2025.
  • In the past 5 years, Regen BioPharma's EPS (Weighted Average and Diluted) ranged from a high of $0.43 in Q4 2022 and a low of -$0.13 during Q4 2024
  • Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$0.03 (2023), whereas its average is $0.0.
  • In the last 5 years, Regen BioPharma's EPS (Weighted Average and Diluted) plummeted by 26763.22% in 2023 and then skyrocketed by 9700.7% in 2025.
  • Over the past 4 years, Regen BioPharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.43 in 2022, then tumbled by 109.28% to -$0.04 in 2023, then crashed by 213.47% to -$0.13 in 2024, then skyrocketed by 92.02% to -$0.01 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.01 for Q2 2025, versus -$0.0 for Q1 2025 and -$0.13 for Q4 2024.